Document Detail


Developing new metal-based therapeutics: challenges and opportunities.
MedLine Citation:
PMID:  17992277     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Unexpected side effects and problems experienced in clinical trials have created a difficult environment for those developing new pharmaceuticals and, as a consequence, the number of new chemical entities being registered has fallen to a historic low. Those developing metal-based therapeutics will face the same difficulties, but this environment also provides many opportunities for creative solutions to be applied to overcoming the problems and concerns. In this perspective, these challenges and opportunities are considered in the context of examples of a number of classes of metal-based therapeutics.
Authors:
Trevor W Hambley
Related Documents :
15137527 - The burden of hospitalised pneumonia in lazio, italy, 1997-1999.
8357747 - Gout and mechanisms of crystal-induced inflammation.
16804837 - The spread of klebsiella pneumoniae carbapenemase-producing k. pneumoniae to upstate ne...
7429727 - Expiation as a defense.
485967 - First aid treatment of burns.
14635557 - Initial burden of disease estimates for south africa, 2000.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-10-04
Journal Detail:
Title:  Dalton transactions (Cambridge, England : 2003)     Volume:  -     ISSN:  1477-9226     ISO Abbreviation:  Dalton Trans     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-09     Completed Date:  2008-02-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101176026     Medline TA:  Dalton Trans     Country:  England    
Other Details:
Languages:  eng     Pagination:  4929-37     Citation Subset:  IM    
Affiliation:
Centre for Heavy Metals Research, School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia. t.hambley@chem.usyd.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Design*
Metals / therapeutic use*
Models, Molecular
Radioisotopes / therapeutic use
Chemical
Reg. No./Substance:
0/Metals; 0/Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeted alpha-therapy: past, present, future?
Next Document:  Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implica...